Scarica l'app Stockscreener
111.42
1.74%
1.91
Dopo l'orario di chiusura:
111.31
-0.11
-0.10%
Veradermics Inc Borsa (MANE) Ultime notizie
Veradermics, Incorporated Revenue Breakdown – NYSE:MANE - TradingView
Veradermics' Oral Hair Loss Drug for Women Shows Results In Just 2 Months - Yahoo Finance
LifeSci Capital Maintains Veradermics(MANE.US) With Buy Rating, Maintains Target Price $170 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Veradermics shares climb 9% after encouraging female hair loss trial results (MANE) - MSN
Veradermics presents subgroup analysis of hair loss drug trial By Investing.com - Investing.com Canada
Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302’ in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy - Yahoo Finance
Veradermics Is Maintained at Buy by Citigroup - Moomoo
MANE Maintained by Citigroup -- Price Target Raised to $160 - GuruFocus
Why Veradermics Stock Fell Today - Quiver Quantitative
Veradermics keeps ‘momentum going’ as baldness drug helps women with hair loss - BioPharma Dive
Veradermics stock jumps again on female hair loss drug win - Clinical Trials Arena
Veradermics jumps after mid-stage trial data for lead drug in female pattern hair loss - MSN
MANE Stock Draws Traders As Volatility And Cash Pile Stand Out - StocksToTrade
Why is MANE stock rising today? - MSN
LifeSci Capital Maintains Veradermics(MANE.US) With Buy Rating, Raises Target Price to $170 - Moomoo
Why Is MANE Stock Rising Today? - TradingView
Buzzy Veradermics shows its oral minoxidil can tackle female pattern hair loss, too - Fierce Pharma
Veradermics (MANE) Sees 13.9% Increase in Stock Price - GuruFocus
Veradermics Hair Loss Pill Shows Strong Phase II Signal in Women - Yahoo Finance
PayPal, Veradermics, Alibaba And Other Big Stocks Moving Higher On Wednesday - Benzinga
Veradermics stock rises 9% on positive hair loss trial data By Investing.com - Investing.com Canada
Veradermics (NYSE: MANE) posts strong VDPHL01 Phase 2 female data - Stock Titan
Veradermics stock rises 9% on positive hair loss trial data - Investing.com
MANE Initiates Coverage by B. Riley Securities -- Price Target S - GuruFocus
Veradermics reports phase 2 hair loss trial results By Investing.com - Investing.com Canada
Up to 90% of women reported better hair coverage by Month 6 - Stock Titan
Veradermics’ Oral VDPHL01 Delivers Positive Study ‘207’ Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study ‘306’ Readout - Yahoo Finance
B.Riley initiates Veradermics stock coverage with Buy on hair loss drug - Investing.com Nigeria
B.Riley initiates Veradermics stock coverage with Buy on hair loss drug By Investing.com - Investing.com India
Veradermics to Hold Conference Call to Discuss Study ‘207’ Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair Loss - BioSpace
Veradermics Announces Encouraging Phase 2 Results for VDPHL01 in Female Pattern Hair Loss with Over 22 Hairs/cm² Average Growth - Kalkine Media
Veradermics to present phase 2 hair loss study results Wednesday - Investing.com
Veradermics to Share Hair Loss Drug Study Results in Wednesday Call - Moomoo
Veradermics to present phase 2 hair loss study results Wednesday By Investing.com - Investing.com Canada
MSN Money - MSN
Veradermics (MANE) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Jefferies Maintains Veradermics(MANE.US) With Buy Rating, Raises Target Price to $182 - Moomoo
Veradermics (MANE) Stock Forecast & Analyst Ratings - Moomoo
Hair loss biotech Veradermics, up 656% since its IPO, credits the obesity boom - BioSpace
MANE Should I Buy - Intellectia AI
Veradermics, Incorporated(NYSE: MANE) added to Russell 2000 Index - marketscreener.com
Veradermics, Incorporated(NYSE: MANE) added to Russell 2000 Value Benchmark - marketscreener.com
Veradermics, Incorporated(NYSE: MANE) added to Russell 2000 Growth Benchmark - marketscreener.com
Veradermics, Incorporated(NYSE: MANE) added to Russell 3000E Growth Benchmark - marketscreener.com
2026 Power 25 Healthcare: Dr. Reid Waldman - Hartford Business Journal
Veradermics, Incorporated(NYSE: MANE) added to Russell 3000 Growth Benchmark - marketscreener.com
Veradermics, Incorporated(NYSE: MANE) added to Russell Small Cap Completeness Index - marketscreener.com
Veradermics, Incorporated Actuals & Estimates (NYSE:MANE) - TradingView
Cantor Fitzgerald reiterates Veradermics stock rating after CEO dinner By Investing.com - Investing.com Australia
MANE Forecast — Price Target — Prediction for 2027 - TradingView
Biotech ETF Index Surges 10% After Rebalance - ETF Database
MANE Stock Pops As Traders Hunt Biotech Momentum - StocksToTrade
Can Veradermics (MANE) Climb 27.65% to Reach the Level Wall Street Analysts Expect? - Yahoo Finance
Should I buy Veradermics Incorporated (MANE) - Zacks Investment Research
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):